Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

NIH

Drug and asset intelligence for NIH with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
4
Catalysts
0
Stage
Development stage unavailable

Recent signals(4)

ClinicalAugust 21, 2026

NIH Initiates First-in-Human Study of Hope inVent Miniature Respirator

The National Institutes of Health Clinical Center is conducting a first-in-human pilot study to evaluate the Hope inVent, a miniature in-line respirator designed for short-term breathing support in emergencies.

CompetitiveAugust 2, 2026

NIH Undiagnosed Diseases Network Aims to Enhance Diagnosis of Rare Conditions

The NIH Undiagnosed Diseases Network (UDN) is established to improve diagnosis and understanding of rare undiagnosed conditions.

ClinicalJuly 28, 2026

NIH Study to Evaluate Hepatitis C Virus Infection in Blood Donors

The NIH is conducting a study to assess the infectivity and natural history of Hepatitis C Virus (HCV) among blood donors who test positive for antibodies.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Genetic Disorders →
Hepatitis C →
Infectious Disease →
Rare Diseases →

Therapeutic areas

Cerebral Palsy and Muscular Dystrophy →
Device →
Genetic Disorders →
Hepatitis C →
Infectious Disease →
Neurology →
Rare Diseases →
Respiratory →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

CompetitiveJune 28, 2026

NIH Investigates Exoskeletons for Children with Mobility Impairments

The NIH is conducting a study on a new exoskeleton device designed to assist children and young adults with mobility issues due to conditions like cerebral palsy and muscular dystrophy.